117 related articles for article (PubMed ID: 17352386)
1. 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists.
Gearry RB; Ajlouni Y; Nandurkar S; Iser JH; Gibson PR
Inflamm Bowel Dis; 2007 Aug; 13(8):1009-15. PubMed ID: 17352386
[TBL] [Abstract][Full Text] [Related]
2. Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.
Ma C; Ascoytia C; McCarrier KP; Martin M; Feagan BG; Jairath V
Dig Dis Sci; 2018 Oct; 63(10):2555-2563. PubMed ID: 29959726
[TBL] [Abstract][Full Text] [Related]
3. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain.
Gisbert JP; Gomollón F; Hinojosa J; López San Román A
J Crohns Colitis; 2010 Nov; 4(5):567-74. PubMed ID: 21122561
[TBL] [Abstract][Full Text] [Related]
4. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.
Castillo-Regalado E; Ríos R; Aràjol C; Gely C; Márquez L; Calafat M; González-Muñoza C; Cañete F; Mesonero F; Guardiola J; Garcia-Planella E; Mañosa M; Domènech E
Gastroenterol Hepatol; 2023 Mar; 46(3):164-170. PubMed ID: 36179946
[TBL] [Abstract][Full Text] [Related]
5. Management of Crohn's disease - are guidelines transferred to clinical practice?
Klag T; Stange EF; Wehkamp J
United European Gastroenterol J; 2015 Aug; 3(4):371-80. PubMed ID: 26279846
[TBL] [Abstract][Full Text] [Related]
6. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
7. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.
Schoepfer AM; Bortolotti M; Pittet V; Mottet C; Gonvers JJ; Reich O; Fournier N; Vader JP; Burnand B; Michetti P; Froehlich F
Aliment Pharmacol Ther; 2014 Oct; 40(8):930-7. PubMed ID: 25146487
[TBL] [Abstract][Full Text] [Related]
8. Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Ma C; Dutton SJ; Cipriano LE; Singh S; Parker CE; Nguyen TM; Guizzetti L; Gregor JC; Chande N; Hindryckx P; Feagan BG; Jairath V
Aliment Pharmacol Ther; 2018 Jul; 48(2):114-126. PubMed ID: 29851091
[TBL] [Abstract][Full Text] [Related]
9. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
10. Current practice in management of Crohn's disease in Wales.
Dhruva PK; Price PE; Torkington J
Surgeon; 2008 Feb; 6(1):26-31. PubMed ID: 18318085
[TBL] [Abstract][Full Text] [Related]
11. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
12. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of chronic inflammatory bowel diseases].
Beglinger C
Ther Umsch; 1997 Nov; 54(11):649-53. PubMed ID: 9454368
[TBL] [Abstract][Full Text] [Related]
14. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
15. [Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection].
Vermeire S; Rutgeerts P
Zentralbl Chir; 1998; 123(4):352-6. PubMed ID: 9622893
[TBL] [Abstract][Full Text] [Related]
16. Gastroenterologists' prescribing of infliximab for Crohn's disease: a national survey.
St Charles M; Smith SR; Beardsley R; Fedder DO; Carter-Pokras O; Cross RK
Inflamm Bowel Dis; 2009 Oct; 15(10):1467-75. PubMed ID: 19266574
[TBL] [Abstract][Full Text] [Related]
17. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
Hinojosa J; Gisbert JP; Gomollón F; López San Román A
J Crohns Colitis; 2012 Aug; 6(7):763-70. PubMed ID: 22398092
[TBL] [Abstract][Full Text] [Related]
18. 5-Aminosalicylic Acid Prevents Disease Behavior Progression and Intestinal Resection in Colonic and Ileocolonic Crohn's Disease Patients: A Retrospective Study.
Wan J; Wang X; Zhang Y; Xue X; Li Y; Liu Z; Han S; Chen M; Nie Y; Shi Y; Liang J; Wu K
Can J Gastroenterol Hepatol; 2021; 2021():1412663. PubMed ID: 34422708
[TBL] [Abstract][Full Text] [Related]
19. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
Maier K; Fischer C; Klotz U; Heinkel K
Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
